Drug intelligence / Profile preview

Annao Tablets

Development stage: Unknown
Lead developer: Zhejiang H.Power Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Annao Tablets (安脑片) is a traditional Chinese medicine (TCM) formulation developed and marketed by Zhejiang H.Power Pharmaceutical for the treatment of neurological and cerebral disorders. Derived from the classical prescription Angong Niuhuang Pills with modified ingredients, it is primarily used for stroke-associated neurological deficits and cerebral ischemia. Research indicates that the tablets exert neuroprotective effects by improving mitochondrial function and quality control mechanisms, demonstrating anti-ischemic properties in animal models of cerebral ischemia-reperfusion injury. It is administered orally as a tablet and is currently approved for use in China.

Brand names: Annao Tablets安脑片
Other names: Annao Pian

Beyond the preview

Go deeper on Annao Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Annao Tablets.

Explore the full profile